Bioventus (BVS) vs SpyGlass Pharma (SGP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Bioventus is the larger company by market cap ($872.3 million vs $799.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | SGP |
|---|---|---|
| Share price | $12.77 | $23.90 |
| Market cap | $872.26M | $799.41M |
| 1-day change | -2.52% | -3.55% |
| YTD return | +71.64% | — |
| 1-year return | +92.03% | — |
| 5-year return | -6.38% | — |
| P/E ratio (TTM) | 16.80 | — |
| Forward P/E | 13.88 | — |
| EPS (TTM) | $0.76 | $-2.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $32.44 |
| 52-week low | $6.37 | $17.06 |
| Distance from 52-week high | -19.65% | -26.33% |
| Average volume | 627.38K | 112.24K |
| Shares outstanding | 68.31M | 33.45M |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
BVS vs SGP FAQ
Which is bigger, Bioventus or SpyGlass Pharma?
Bioventus (BVS) is larger, with a market capitalization of $872.26M compared with $799.41M for SpyGlass Pharma (SGP).
Are Bioventus and SpyGlass Pharma in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.